AffiliationInnovative Immunotherapies Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Hospital Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
MetadataShow full item record
AbstractThe recent successes of clinical trials with T cells genetically modified with either clonal T cell receptors or chimeric antigen receptors have also highlighted their potential toxicities. The aim of this focused review was to describe the adverse events observed in these clinical trials and to link them to the complex biology of genetically targeted T cells. Finally, strategies to overcome these toxicities will be proposed and discussed, including the use of suicide genes and other innovative gene therapy strategies.
CitationOvercoming the toxicity hurdles of genetically targeted T cells. 2015, 64 (1):123-30 Cancer Immunol Immunother
JournalCancer Immunology, Immunotherapy
- Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy.
- Authors: Ren YB, Sun SJ, Han SY
- Issue date: 2018
- Biomarkers in T-cell therapy clinical trials.
- Authors: Lacey SF, Kalos M
- Issue date: 2013 Jun
- CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma.
- Authors: Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, Gentner B, Gullotta F, Ponzoni M, Bernardi M, Marcatti M, Saudemont A, Bordignon C, Savoldo B, Ciceri F, Naldini L, Dotti G, Bonini C, Bondanza A
- Issue date: 2013 Nov 14
- Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors.
- Authors: Marcu-Malina V, van Dorp S, Kuball J
- Issue date: 2009 May
- Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells.
- Authors: van Loenen MM, de Boer R, Hagedoorn RS, Jankipersadsing V, Amir AL, Falkenburg JH, Heemskerk MH
- Issue date: 2013 Aug